A5029465085- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Estrogen and related hormone effects
- Colorectal Cancer Surgical Treatments
- Prostate Cancer Treatment and Research
- Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Vascular Tumors and Angiosarcomas
- Bladder and Urothelial Cancer Treatments
- Biosimilars and Bioanalytical Methods
- CAR-T cell therapy research
- Colorectal and Anal Carcinomas
- Ear and Head Tumors
- Lung Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Ferroptosis and cancer prognosis
Mahidol University
2016-2025
Ramathibodi Hospital
2016-2025
Roche (Switzerland)
2024
Inhibrx (United States)
2024
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines diagnosis, treatment and follow-up patients with endometrial cancer was published in 2022. It therefore decided, by both ESMO Indian Paediatric (ISMPO), to convene a virtual meeting July 2022 adapt guidelines take into account variations management Asia. These represent consensus opinion panel Asian experts representing oncological societies China (CSCO), India Indonesia (ISHMO), Japan...
One-year of immune checkpoint inhibitor (ICI) treatment after concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer (NSCLC) is a standard care. The precise predictive biomarkers are under investigations either immunological markers or clinical characteristics. Here, we explored repertoire T receptor β-chain (TCRβ) during ICI treatment. During August 2019 and September 2021, NSCLC, post CCRT patients from Ramathibodi Hospital was enrolled. All were treated by...
Abstract Background EGFR inhibitor and immunotherapy have been approved for adjuvant treatment in resectable non-small cell lung cancer (NSCLC). Limited reports of molecular clinical characteristics as prognostic factors NSCLC published. Methods Medical records patients with stage I–III diagnosed during 2015–2020 were reviewed. Real time-PCR (RT-PCR) was performed mutations ( EGFRm ). Immunohistochemistry staining conducted ALK PD-L1 expression. Categorical variables compared using...
•This article provides ESMO recommendations adapted for the treatment of early breast cancer in Asian patients.•It outlines clinical diagnosis, staging, management, and follow-up patients with cancer.•The applicability regarding availability reimbursement practices are described each region.•The aim is to encourage evidence-based medicine facilitate drug registration across different regions Asia. The European Society Medical Oncology (ESMO) Clinical Practice Guidelines were updated...
Abstract Background The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 −) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI) plus CDK4/6 inhibitors (CDK4/6i). Direct comparison trials different CDK4/6i are scarce. This real-world study compared the effectiveness AI ribociclib versus palbociclib. Methods multicenter retrospective cohort study, conducted in six centers Thailand, enrolled...
In the pivotal Bevacizumab-Avastin Adjuvant (AVANT) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% 75%, respectively, adjuvant fluorouracil oxaliplatin-based chemotherapy; however, trial did not demonstrate a disease-free (DFS) benefit adding bevacizumab to chemotherapy in III CC suggested detrimental effect on OS. The Long-term Survival AVANT (S-AVANT) study was designed collect extended follow-up for trial.To explore...
Abstract This study aimed to assess the cost-utility and budget impact of dual single HER2 targeted neoadjuvant therapy for HER2-positive breast cancer in Sri Lanka. A five-health state Markov model with lifetime horizon was used trastuzumab (T) plus pertuzumab (P) or lapatinib (L) compared T chemotherapy (C), public healthcare system societal perspectives. Input parameters were estimated using local data, network meta-analysis, published reports literature. Costs adjusted year 2021 (1USD =...
The risk of late distant recurrence (LDR) estrogen receptor (ER)-positive breast cancer continues even after 5 years endocrine treatment. Clinical Treatment Score (CTS5) was developed and validated as a tool to assess the LDR using data from Tamoxifen, Arimidex Alone or in Combinations (ATAC) Breast International Group 1-98 (BIG1-98) trials. This study aimed externally validate CTS5 real-world cohort patients treated at an academic center Thailand.The retrospective analytical research...
Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the mortality-to-incidence ratio, we compared access BC drugs Thailand other Asian countries.BC experts involved International Group (BIG)-Asia six representative groups for countries or special administrative region (SAR) Asia (Hong Kong SAR, Japan, Korea, Taiwan, Thailand, and Singapore)...
BIM is a modulator of apoptosis that triggered by EGFR-TKIs. This study evaluated the role deletion and its expression as predictor EGFR-TKI treatment outcome.The medical record 185 EGFR-positive advanced non-small cell lung cancer (NSCLC) patients with/ without between 9/2012 12/2014 were retrospectively reviewed. polymorphism tested RT-PCR immunohistochemistry, respectively. Survival outcomes in EGFR-TKI-treated analyzed according to sequence EGFR mutation. The correlation polymorphism,...
Sister Mary Joseph nodule is an uncommon metastatic intra-abdominal malignancy involving the umbilicus. The present study describes a rare case of desmoplastic small round cell tumor (DSRCT), histological grade 3, high grade, Gilly classification 4, stage IV, in 18-year-old Thai man presenting with nodule, ascites and pleural effusion. histopathological examination umbilical mass revealed presence malignant cells associated prominent stromal desmoplasia. Immunohistochemical stains showed...
e16622 Background: Bladder cancer constitutes a notable etiological factor in kidney disease, precipitating acute injuries (AKI) through mechanisms such as post-renal obstruction, with the potential for progression to chronic disease (CKD) over time. The objective of this study is systematically evaluate correlation between bladder and manifestation or across various stages, focus on hospitalized patients undergoing treatment cancer. Methods: 2020 United States National Inpatient Sample...
PURPOSE Breast cancer progression varies across molecular subtypes, and treatment options for human epidermal growth factor receptor 2 (HER2)-low expression tumors are limited compared with those of HER2 overexpression tumors. Comprehensive information regarding the epidemiology clinical outcomes metastatic HER2-low breast in a Southeast Asian population is lacking. METHODS This retrospective cohort study was performed to analyze data from patients de novo advanced cancer, including...
Background Despite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with EGFR -mutated NSCLC, access remains limited Thailand and elsewhere. Methods Retrospective analysis locally advanced/recurrent NSCLC known mutation ( m) status treated at Ramathibodi Hospital (2012–2017). Prognostic factors for overall survival (OS), including type healthcare coverage, were analyzed using Cox regression. Results Of 750 patients, 56.3%...
e17571 Background: Abiraterone acetate and prednisolone (AAP) + ADT has been approved for treatment metastatic castration-resistant prostate cancer (CRPC) in the standard dose 1,000 mg with fasting state. Data Ramathibodi hospital showed patients who had treated of (AA); PSA response 47.83%. Previous studies using low AA 250 food non-inferiority results efficacy. was not be reimbursed Thailand, so ability to use a highly effective drug at quarter dose, could help patient accessibility...